Fully funded by 
Content independently selected
An 11-year population-based propensity-matched analysis.
Large cohort study shows 52% lower risk for death, 34% reduced risk for HCC.
Findings also refute suggestions of more aggressive disease.
REACH-2 study of biomarker-selected patients.
Phase 2 data show 37.5% pCR, no delays to surgery.
New option for patients who previously took sorafenib
Results echo previous findings in heart, lung, and kidney transplant.
Retrospective analysis provides evidence of improved outcome.
The decision is based on clinical evidence from the RESORCE trial of regorafenib vs best supportive care in hepatocellular carcinoma
SVR reduces, but does not eliminate, HCC risk.
Tenofovir may confer better protection than entecavir.
Similar outcomes despite larger NAFLD-HCC tumor size.
3-year data from a phase 2 study with mFOLFOX6 + BV.
NCDB analysis shows benefit regardless of tumor size or degree of underlying fibrosis.
Similar short-term outcomes vs nonmultinodular disease.
Chinese medicine delivers results in meta-analysis.
Global multicohort study finds effect independent of HCC stage, treatment, or location.
